Zinc Supplementation and Cardiovascular Risk in HIV
| Status: | Active, not recruiting |
|---|---|
| Conditions: | HIV / AIDS |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 10/17/2018 |
| Start Date: | September 2016 |
| End Date: | August 2021 |
The purpose of this pilot study is to determine whether zinc supplementation significantly
affects immune activation in HIV-infected subjects.
affects immune activation in HIV-infected subjects.
Inclusion Criteria:
- HIV-1 infection
- Age ≥18 years
- Zinc level ≤0.75 mg/L
- Receiving a stable antiretroviral regimen with no plans to change during study
- Documentation of an HIV-1 RNA level of ≤400 copies/mL
- No diarrhea or nausea/vomiting for the last month
Exclusion Criteria:
- Pregnancy/lactation
- Presence of inflammatory condition
- Regular use of agents that may affect inflammation in the last 3 months. The regular
use of NSAIDS, aspirin, or statins will be allowed as long as dose has been stable for
the last 3 months and is not expected to change during the study.
- Presence of active neoplastic diseases requiring chemotherapy and/or use of
immunosuppressive drugs
- Known cardiovascular disease
- Uncontrolled diabetes
- Allergy or intolerance to zinc sulfate.
- AST and ALT > 2.5 x ULN
- Hemoglobin < 9.0 g/dL
- GFR <50 mL/min
We found this trial at
1
site
Click here to add this to my saved trials
